









Markets
/
Stocks
/
nasdaq-bway
/

Brainsway Ltd

BWAY

15.960USD

-0.100-0.62%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

603.12MMarket Cap

112.86P/E TTM



Brainsway Ltd

15.960

-0.100-0.62%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

36 / 207

Overall Ranking

119 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

18.000

Target Price

+12.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 50.92% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.02M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 2.92M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 110.33, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.33M shares, increasing 7.53% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 283.86K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.10.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.49, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 12.63M, representing a year-over-year increase of 26.26%, while its net profit experienced a year-over-year increase of 237.83%.

Score

Industry at a Glance

Previous score

9.49

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.78

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.66

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is 111.02, which is -12.84% below the recent high of 96.77 and 109.27% above the recent low of -10.29.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Brainsway Ltd is 18.00, with a high of 19.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

18.000

Target Price

+12.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Brainsway Ltd

BWAY

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 9.18, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 17.27 and the support level at 14.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.18

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.165

Neutral

RSI(14)

58.980

Neutral

STOCH(KDJ)(9,3,3)

53.926

Neutral

ATR(14)

0.769

High Vlolatility

CCI(14)

87.866

Neutral

Williams %R

43.697

Buy

TRIX(12,20)

0.762

Sell

StochRSI(14)

26.480

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

15.954

Buy

MA10

15.907

Buy

MA20

15.678

Buy

MA50

13.662

Buy

MA100

12.207

Buy

MA200

10.987

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 38.85%, representing a quarter-over-quarter decrease of 0.29%. The largest institutional shareholder is James Simons, holding a total of 283.86K shares, representing 1.50% of shares outstanding, with 14.62% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Valor Equity Partners

2.10M

Masters Capital Management, L.L.C.

1.00M

Phoenix Financial Ltd

697.26K

+190.09%

Phoenix Investment and Finances Ltd

403.99K

-16.31%

Acadian Asset Management LLC

336.58K

-4.63%

Essex Investment Management Company, LLC

303.17K

-0.75%

Renaissance Technologies LLC

Star Investors

298.26K

-9.52%

Shulkin (Jonathan K.)

268.25K

Gracias (Antonio J)

243.50K

ARK Investment Management LLC

Star Investors

188.33K

+7.26%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 5.07, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.